PIK3CA Somatic variants

About

Biomarker type: Somatic variant

Gene context: PIK3CA

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (1) ER positive, HER2-negative, PIK3CA Somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA Somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
FDA (1) ER positive, HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Capivasertib, Fulvestrant
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA Somatic variants Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) FDA (1) ER positive, HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Fulvestrant, Inavolisib, Palbociclib
EMA (1) ER positive, HER2-negative, PIK3CA Somatic variants Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA Somatic variants, PR positive Invasive Breast Carcinoma Alpelisib, Fulvestrant
EMA (1) ER positive, HER2-negative, PIK3CA Somatic variants Invasive Breast Carcinoma Capivasertib, Fulvestrant